Advertisement
Advertisement
RGEN
Repligen Corp
142.87
USDSponsored
-0.73
-0.51%
Jul 31, 15:05 UTC -4
Open
RGEN Earnings Reports
Positive Surprise Ratio
RGEN beat 36 of 43 last estimates.
84%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$210.65M
/$0.47
Implied change from Q2 26 (Revenue/ EPS)
+3.19%
/-12.96%
Implied change from Q3 25 (Revenue/ EPS)
+11.57%
/+2.17%
Repligen Corp earnings per share and revenue
On Jul 28, 2026, RGEN reported earnings of 0.54 USD per share (EPS) for Q2 26, beating the estimate of 0.45 USD, resulting in a 18.01% surprise. Revenue reached 204.13 million, compared to an expected 205.51 million, with a -0.67% difference. The market reacted with a +10.90% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 19 analysts forecast an EPS of 0.47 USD, with revenue projected to reach 210.65 million USD, implying an decrease of -12.96% EPS, and increase of 3.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
PTC Therapeutics, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.41
Actual
$0.92
Surprise
+122.65%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.37%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.52
Actual
$14.29
Surprise
+35.73%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.84
Surprise
+16.03%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
FAQ
What were Repligen Corp's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Repligen Corp reported EPS of $0.54, beating estimates by 18.01%, and revenue of $204.13M, -0.67% below expectations.
How did the market react to Repligen Corp's Q2 2026 earnings?
The stock price moved up 10.9%, changed from $131.06 before the earnings release to $145.34 the day after.
When is Repligen Corp expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Repligen Corp's next earnings report?
Based on 19
analysts, Repligen Corp is expected to report EPS of $0.47 and revenue of $210.65M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement